Bellusci Lorenza, Grubbs Gabrielle, Sait Shaimaa, Herbst Katherine W, Salazar Juan C, Khurana Surender
Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20871, USA.
Division of Pediatric Infectious Diseases, Connecticut Children's, Hartford, CT 06106, USA.
Vaccines (Basel). 2024 Jun 7;12(6):638. doi: 10.3390/vaccines12060638.
There is minimal knowledge regarding the durability of neutralization capacity and level of binding antibody generated against the highly transmissible circulating Omicron subvariants following SARS-CoV-2 infection in children with acute COVID-19 and those diagnosed with multisystem inflammatory syndrome in children (MIS-C) in the absence of vaccination. In this study, SARS-CoV-2 neutralization titers against the ancestral strain (WA1) and Omicron sublineages were evaluated in unvaccinated children admitted for COVID-19 ( = 32) and MIS-C ( = 32) at the time of hospitalization (baseline) and at six to eight weeks post-discharge (follow-up) between 1 April 2020, and 1 September 2022. In addition, antibody binding to the spike receptor binding domain (RBD) from WA1, BA.1, BA.2.75, and BA.4/BA.5 was determined using surface plasmon resonance (SPR). At baseline, the children with MIS-C demonstrated two-fold to three-fold higher binding and neutralizing antibodies against ancestral WA1 compared to those with COVID-19. Importantly, in children with COVID-19, the virus neutralization titers against the Omicron subvariants at six to eight weeks post-discharge reached the same level as those with MIS-C had at baseline but were higher than titers at 6-8 weeks post-discharge for MIS-C cases. Cross-neutralization capacity against recently emerged Omicron BQ.1, BQ.1.1, and XBB.1 variants was very low in children with either COVID-19 or MIS-C at all time points. These findings about post-infection immunity in children with either COVID-19 or MIS-C suggest the need for vaccinations in children with prior COVID-19 or MIS-C to provide effective protection from emerging and circulating SARS-CoV-2 variants.
对于未接种疫苗的急性新冠病毒感染儿童和被诊断为儿童多系统炎症综合征(MIS-C)的儿童,在感染新冠病毒2(SARS-CoV-2)后,针对高传播性的循环奥密克戎亚变体产生的中和能力的持久性和结合抗体水平的了解极少。在本研究中,于2020年4月1日至2022年9月1日期间,对因新冠病毒感染住院(基线)时和出院后六至八周(随访)时的未接种疫苗的新冠病毒感染儿童(n = 32)和MIS-C儿童(n = 32),评估了针对原始毒株(WA1)和奥密克戎亚谱系的SARS-CoV-2中和滴度。此外,使用表面等离子体共振(SPR)测定了抗体与WA1、BA.1、BA.2.75和BA.4/BA.5的刺突受体结合域(RBD)的结合情况。在基线时,与新冠病毒感染儿童相比,MIS-C儿童针对原始WA1的结合抗体和中和抗体高两到三倍。重要的是,在新冠病毒感染儿童中,出院后六至八周时针对奥密克戎亚变体的病毒中和滴度达到了与MIS-C儿童基线时相同的水平,但高于MIS-C病例出院后6 - 8周时的滴度。在所有时间点,新冠病毒感染儿童或MIS-C儿童针对最近出现的奥密克戎BQ.1、BQ.1.1和XBB.1变体的交叉中和能力都非常低。这些关于新冠病毒感染儿童或MIS-C儿童感染后免疫的发现表明,先前感染过新冠病毒或患有MIS-C的儿童需要接种疫苗,以提供针对新出现的和正在传播的SARS-CoV-2变体的有效保护。